Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

y regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products. In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen's products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products. In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for its products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products. Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

The scientific information discussed in this news release related to Amgen's product candidates is preliminary and investigative. Such product candidates are not approved by the U.S.
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... ... ... PRXL ), a leading global biopharmaceutical services,organization, today announced the ... technology organization. By combining,ClinPhone with Perceptive Informatics, PAREXEL,s wholly-owned technology,subsidiary, ...
... p.m. ET Today -, SUNNYVALE, Calif., Aug. 14 ... its fourth quarter,and fiscal year ended June 30, 2008. The ... million, or $0.18 per share, compared to a net loss ... of fiscal 2007., Total operating expenses were $4.8 million ...
... aerospace and ocean engineering at Virginia Tech, has received ... Junior Faculty Award. The award will support Philen,s research ... material and structural systems that have the unique ability ... these innovative materials will lead to new and exciting ...
Cached Biology Technology:PAREXEL Closes the Acquisition of ClinPhone 2PAREXEL Closes the Acquisition of ClinPhone 3PAREXEL Closes the Acquisition of ClinPhone 4PAREXEL Closes the Acquisition of ClinPhone 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6
(Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
(Date:7/11/2014)... National Institute of Standards and Technology (NIST) need ... effectively, they often prove that necessity is truly ... recently for M. Lorna De Leoz and Stephen ... of glycomics. Glycomics is the study of the ... attached to proteins and lipids and influence cellular ...
(Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2Baboons groom early in the day to get benefits later 2
... 14, 2011In a letter to Maine,s two Senators, Susan Collins ... Broihier, MS, RD., said, "I would like to thank you ... that,s particularly important to our statethe amount of potatoes and ... lunch program. Broihier wrote, "First, there is no question ...
... the palo verde, mesquite and acacia trees throughout the Southwestern ... survival of their offspring against the parasitic wasp species that ... are the seed beetles Mimosestes amicus , living all ... all but invisible to our eyes or nearly so. ...
... 14, 2011 As the United States nears another ... (BGU) have determined scientifically, for the first time, that ... According to Prof. Hagit Cohen from the Anxiety ... Sciences, "We understand that emotional changes are related and ...
Cached Biology News:This beetle uses eggs as shields against wasps 2This beetle uses eggs as shields against wasps 3This beetle uses eggs as shields against wasps 4This beetle uses eggs as shields against wasps 5Voting causes stress according to Ben-Gurion University of the Negev study 2
CELLine System cultivation flask (for secreted products)...
... StabilCoat Plus Microsphere/Microarray Stabilizer is an aqueous ... and other non-toxic chemicals in a PBS ... 7.4. This product contains a combination ... a preservative. StabilCoat Plus Stabilizer provides ...
... The mini incubation trays are ... to screen antigens that have ... Each tray has eight 10.5 ... that accommodate strips cut from ...
... designed for quick and easy protein purification ... two 0.25mm holes laser cut at the ... remain liquid-tight during incubation of the gel ... protein diffuses from the gel into the ...
Biology Products: